Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Net Cash Flow (2019 - 2025)

Historic Net Cash Flow for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to -$4.1 million.

  • Biodesix's Net Cash Flow rose 6186.07% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.8 million, marking a year-over-year decrease of 22796.99%. This contributed to the annual value of -$39000.0 for FY2024, which is 9976.79% up from last year.
  • Biodesix's Net Cash Flow amounted to -$4.1 million in Q3 2025, which was up 6186.07% from $3.1 million recorded in Q2 2025.
  • Over the past 5 years, Biodesix's Net Cash Flow peaked at $30.7 million during Q2 2024, and registered a low of -$17.8 million during Q1 2023.
  • Over the past 5 years, Biodesix's median Net Cash Flow value was -$6.9 million (recorded in 2021), while the average stood at -$2.4 million.
  • As far as peak fluctuations go, Biodesix's Net Cash Flow tumbled by 56217.3% in 2021, and later skyrocketed by 109205.88% in 2022.
  • Quarter analysis of 5 years shows Biodesix's Net Cash Flow stood at -$15.2 million in 2021, then skyrocketed by 283.63% to $27.9 million in 2022, then tumbled by 76.91% to $6.4 million in 2023, then plummeted by 180.09% to -$5.2 million in 2024, then rose by 20.09% to -$4.1 million in 2025.
  • Its Net Cash Flow stands at -$4.1 million for Q3 2025, versus $3.1 million for Q2 2025 and -$8.6 million for Q1 2025.